References.

1 Clark James H. **1999** Green chemistry: challenges and opportunities . *Green Chemistry 1-8*

2 Organic process research and development **2010** Green chemistry highlights.,(14), 770-780. *American chemical society*

3 Sheldon Roger A. **2007** Green Chemistry, cutting-edge research for a greener sustainable future. *Royal society of chemistry .(9) 1261-1384*

4 Menavar Raza , Indra K Reddy **2010** Chirality in drug design and development Texas A&M university school of pharmacy Kingsville, *Marcel Dekker, Inc*

5 Kelley P., Faian Laszlo and Pratt Carolyn **2011** Failures of fractional crystallization: Ordered co crystals of isomers and near isomers Steven *Brock Acta Cryst*. B67, 79-93.

6 World bank group **1998** Pharmaceutical manufacturing, pollution prevention and abatement handbook *Pollution Prevention and Abatement Handbook.*

7 Carvalho1P. O. , Cass Q. B. , Calafatti S. A., Contesini F. J. 1 and Bizaco R. **2006** Review alternatives for the separation of drug enantiomer *Brazilian Journal of chemical engineering* (23), no 03, 291-300

8 Hutt,A.J.Valentova,J. **2003** The chiral switch: The development of single enatiomer drugs from racemates. *ACTA facultatis pharmaceuticae universitatis comenianae tomus l 2003*

9. Farah,Andrew MD **2002** Clinical focus. *Primary Psychiatry.*;9(12):30-35

10 Miles J. **2009** The patentability of chiral drugs post-: the more things change, the more they stay the same *Berkeley Technology Law Journal. Vol. 24:129*

11 Tundo and P.T.Anastas **1999** Green chemistry: Challenging perspectives, ed.p.,*oxford science, oxford*

12 Sheldon R.A.,chem..Ind,**1997**,12 and 1992,903

13 Ratton S., chim.oggi,**1998**,33

14 Anastas P. and Warner J.C. **1998** Green chemistry: Theory and practice, eds.,*oxford university press , oxford,*

15 Clark J.H.. **1994** Catalysis of organic reactions by supported inorganic reagents, *VCH new York,*

16 Clark J.H. and D.J.Macquarrie, **1998** *chem. Communication*,853

17 Ariens, E.J.; **1988** The acceptable face of intenational completion. Stereophobia: an economic afterthough. *Trends pharmacol .sci*,9,317

18 Berry, B.W.;Jamali, F. **1989** Enantiomeric interaction of flurbiprofen in the rat. *J.Pharma.sci* ,78,632-634

19 Addadi L.Gati, ELahav,M & Leiserowitz,L **1977** Isr.J.chem.15,116-123

20 Albano. V.G.Bellon,P.L. & sansoni, M **1969**, *chem., commun*, pp899-901.

21 United Kingdom her majesty Inspectorate **1993** chief inspectors guidance to inspectors

22 Environmental protection act **1990**, process guidance note IPR 4/9

23 Mills, R.F.N., Adams, S.S., Cliffe, E.E., Dickinson, W., and Nicholson, J.S., **1973** The Metabolism of Ibuprofen, *Xenobiotica,* 3, 589-598

24 Miyako, E., Maruyama, T., Kamiya, N., and Goto, M. **2003** Enzyme-facilitated Enantioselective Transport of (*S*)-Ibuprofen through a Supported Liquid Membrane Based on Ionic Liquids, Chem. Commun., 7 (23), 2926-2927

25 Aldershot, Ashgate CHALLENER, C.A.: Chiral Drugs. **2001**.

26 TUCKER, G.: Chiral switches. **2000** Lancet. 355, , p. 1085-1087.

27 Jadav **2003** Process for converting stereoisomers of sertraline into sertraline *United states patent Patent No US 6506940 B1 Date of Patent Jan 14*.